ATE519493T1 - Blockierendes peptid für die sekretion von entzündungszellen - Google Patents

Blockierendes peptid für die sekretion von entzündungszellen

Info

Publication number
ATE519493T1
ATE519493T1 AT02756467T AT02756467T ATE519493T1 AT E519493 T1 ATE519493 T1 AT E519493T1 AT 02756467 T AT02756467 T AT 02756467T AT 02756467 T AT02756467 T AT 02756467T AT E519493 T1 ATE519493 T1 AT E519493T1
Authority
AT
Austria
Prior art keywords
secretion
present
inflammatory cell
cell secretion
blocking peptide
Prior art date
Application number
AT02756467T
Other languages
English (en)
Inventor
Linda Martin
Kenneth Adler
Yuehua Li
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of ATE519493T1 publication Critical patent/ATE519493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02756467T 2001-06-26 2002-06-26 Blockierendes peptid für die sekretion von entzündungszellen ATE519493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30093301P 2001-06-26 2001-06-26
PCT/US2002/022270 WO2003000027A2 (en) 2001-06-26 2002-06-26 Blocking peptide for inflammatory cell secretion

Publications (1)

Publication Number Publication Date
ATE519493T1 true ATE519493T1 (de) 2011-08-15

Family

ID=23161217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756467T ATE519493T1 (de) 2001-06-26 2002-06-26 Blockierendes peptid für die sekretion von entzündungszellen

Country Status (10)

Country Link
US (2) US20030013652A1 (de)
EP (1) EP1411967B1 (de)
JP (1) JP4610891B2 (de)
AT (1) ATE519493T1 (de)
AU (1) AU2002322475B2 (de)
CA (1) CA2452123A1 (de)
DK (1) DK1411967T3 (de)
ES (1) ES2369760T3 (de)
PT (1) PT1411967E (de)
WO (1) WO2003000027A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
EP2399599A3 (de) 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Muzinhypersektretionsinhibitoren und Verwendungsverfahren
AU2006311458C1 (en) 2005-11-10 2013-05-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
BRPI0714953A2 (pt) * 2006-07-26 2013-07-16 Biomarck Pharmaceuticals Ltd mÉtodos para atenuar a liberaÇço de mediadores inflamatàrios e peptÍdeos éteis nesse sentido
RU2674259C2 (ru) 2010-06-16 2018-12-06 Эмбера Ньюротерапьютикс, Инк Композиции и способы лечения зависимости, психических расстройств и нейродегенеративного заболевания
US9408886B2 (en) 2013-04-05 2016-08-09 Biomarck Pharmaceuticals, Ltd. Inhibitors of metastasis
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
EP3592350B1 (de) 2017-03-10 2025-03-05 Embera NeuroTherapeutics, Inc. Pharmazeutische zusammensetzungen enthaltend metyrapon and oxazepam und verwendungen davon
AU2020298130A1 (en) 2019-06-17 2022-01-20 Biomarck Pharmaceuticals Ltd. Peptides and methods of use thereof in treating uveitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
CA2102142A1 (en) * 1993-03-30 1994-10-01 Andrew J. Ghio Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
EP1154786B1 (de) * 1999-02-24 2004-10-13 North Carolina State University Zusammensetzungen zur modulierung der schleimsekretion
US6506779B1 (en) * 1999-12-03 2003-01-14 Pfizer Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
ITTO20030856A1 (it) * 2003-10-31 2005-05-01 Skf Ab Attuatore lineare a vite a ricircolo di sfere con un dispositivo di sbloccaggio di sicurezza.

Also Published As

Publication number Publication date
CA2452123A1 (en) 2003-03-01
EP1411967B1 (de) 2011-08-10
WO2003000027A2 (en) 2003-01-03
EP1411967A2 (de) 2004-04-28
HK1065702A1 (en) 2005-03-04
WO2003000027A3 (en) 2003-05-08
DK1411967T3 (da) 2011-11-28
AU2002322475B2 (en) 2008-02-21
JP4610891B2 (ja) 2011-01-12
PT1411967E (pt) 2011-09-30
US20030013652A1 (en) 2003-01-16
US20040180836A1 (en) 2004-09-16
EP1411967A4 (de) 2004-12-15
JP2005519850A (ja) 2005-07-07
ES2369760T3 (es) 2011-12-05

Similar Documents

Publication Publication Date Title
SG170082A1 (en) Methods for regulating inflammatory mediators and peptides useful therein
ATE519493T1 (de) Blockierendes peptid für die sekretion von entzündungszellen
DK1015622T3 (da) Praktisk sialylering in vitro af rekombinante glycoproteiner
ATE365210T1 (de) Glykosylierte proteine mit reduzierter allergenität
NZ515718A (en) Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
WO2001034646A3 (en) Recombinant gelatins
IT1284268B1 (it) Procedimento per la produzione di lamierino magnetico a grano orientato, con elevate caratteristiche magnetiche, a partire da
DE50109164D1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
MXPA05013202A (es) Tableta de multiples capas oralmente dispersable.
BR0206961A (pt) Elemento de mola e automóvel
MXPA04002562A (es) Combinacion de un pde-4 y nsaid.
IL150703A (en) Selective electrochemical reduction of halogenated 4 - aminopicolinic acids
AU2002357160A8 (en) Copper deposition using copper formate complexes
NO20044898L (no) Nye etonogestrel estere
DK1419163T3 (da) Tricykliske imidazopyridiner
WO2007075438A3 (en) Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
DE502007000372D1 (de) Schaumstoffsysteme, Kits und deren Verwendung
ATE313272T1 (de) Direkt verpressbarer rohstoff für komprimate
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
DE60237904D1 (de) Ladungspumpe
TW200741132A (en) Luminescent element
IL158278A0 (en) Chitosan and hydroxy carboxylic acid based porous and non-porous matrices
SE9802507D0 (sv) Novel salts
DE59502901D1 (de) Leiterplattenrelais mit einpressanschlüssen
WO2003046139A3 (en) CRBs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHOD OF USE

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411967

Country of ref document: EP